Surgalign Holdings announced a key milestone for its recently introduced posterior fixation platform – the Cortera Spinal Fixation System. Surgalign received FDA 510(k) in August 2022 and Cortera and was introduced in a limited market release shortly thereafter. In a little over three months, the Company has successfully penetrated target markets and today announced the completion of the 100th case utilizing this new flagship pedicle screw system. During this initial market release, Surgalign’s goal has been to collect clinical and design feedback on the system from a wide range of spine surgeons, representing the user needs and preferences of the broader market. Efforts are now underway to secure additional products and the Company intends to ramp up commercialization in the first half of 2023 as it looks to grow its market share in the estimated $2.2B US posterior fixation market.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRGA:
- Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System
- Surgalign™ Expands Adoption of its HOLO Portal™ Surgical Guidance System in Virginia
- Surgalign Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Surgalign™ Announces Corporate Restructuring Program to Focus on Key Growth Areas
